transition to fibrils. Our approach takes advantage of these intermediates to target these peptides in a conformation-and chemical property-specific manner. We designed a library of small molecule a-helical mimetics, specifically oligoquinolines and oligopyrrolamides, that present surface functionalities in a well-defined order to mimic the residues at position i, i þ3/þ4, and iþ7, of the helical surface. The rationale is to stabilize these peptides, thereby preventing their oligomerization and fibrillation, by matching the scaffold sidechains to complementary residues in the helical peptide domain. Previously we showed that the oligoquinoline 5, with alternating negatively-charged and hydrophobic side-chains, is a potent antagonist of Ab aggregation. Here we have investigated whether 5 maintains inhibitory potential in the presence of zinc, a metal ion that has been reported to associate with Ab and affect its conformation, aggregation, and toxicity. Other work on oligopyrrolamides demonstrated their antagonistic effects on IAPP aggregation and toxicity. Due to the similarity between IAPP and Ab, oligopyrrolamides were also screened against Ab. Our results show that ADH-120 is a potent inhibitor of Ab aggregation but only in the absence of zinc. Biophysical assays were used to compare the activity of 5 and ADH-120 against Ab, both in the presence and absence of zinc, as well as to determine trends in Ab inhibition within the oligopyrrolamide library to elucidate structure-activity relationship of the scaffold. To understand how TTP is targeted by gold complexes, the interactions between the model gold complex, [Au(III)(terpy)Cl]Cl 2 (Auterpy) and TTP were investigated using a combination of optical spectroscopy and native electrospray ionization mass spectrometry (ESI-MS) as well as X-ray absorption study (XAS). We discovered that gold exchanges with zinc bound to TTP forming a series of Au x -TTP-2D complexes, with reduction of the gold from Au 3þ to Au 1þ . These protein is then functionally inactive (no RNA binding). When the same experiments were performed with TTP bound to RNA, the Zn-TTP/RNA complex is not disrupted by Auterpy providing potential evidence possible mechanism for its anti-inflammatory properties. To understand how H 2 S, a naturally occurring signaling molecule, targets Zn-TTP, its reactivity was determined using a combination of cryo-ESI-MS, fluorescence and electron paramagnetic resonance (EPR) spectroscopies. We discovered the H 2 S oxidizes the cysteine residues of Zn-TTP via a mechanism that involves atmospheric oxygen, a persulfide intermediate and a radical reaction. The results of both studies will be presented in the context of TTP's biological role. Recently, the structural basis of epitope recognition by vaccine-elicited human monoclonal antibodies (mAbs) specific for the Plasmodium falciparum (Pf) circumsporozoite protein (CSP) repeat region (containing NANP repeats interspersed with NVDP repeats) and the preceding N-terminal junction was detailed. Here we examined the interactions of mAbs isolated from RTS,S/AS01 (RTS,S) vaccinees with CSP antigens using Biolayer Interferometry and Surface Plasmon Resonance. Optimal epitope recognition of mAbs was examined for the NANP repeats, NANP and NVDP residues containing heterologous repeats, and the N-terminal junction peptide (N-JP) dual specificity, which was reported previously for a potent protective antibody against malaria. Here we show that mAbs that avidly (10-50 nM apparent K d [AppK d ]) bound to 1-1.5 NANP repeat containing peptide (NPNA2) also bound to all the other repeat peptides tested. In contrast, mAbs that bound weakly (AppK d R 1mM) to NPNA2, required two NANP repeats (NPNA3) for avid binding. For 3 out of the 4 mAbs tested, the heterologous repeat peptide binding was similar to that of homologous NANP repeat peptide NPNA3, if NVDP residues were upstream of the NANP residues, but was drastically decreased (>100 fold higher AppK d ) when the order was reversed. Remarkably, although the N-JP was not included in the RTS,S vaccine, the mAbs tested recognized this peptide (1-150 nM apparent K d ). These data are partly consistent with the ability of previously reported RTS,S vaccine-induced mAbs to recognize NVDP repeat-containing epitopes. Most importantly, our results reveal the additional specificity of some of the RTS,S-elicited mAbs to the N-JP that was previously observed for the potent protective mAbs isolated from attenuated Pf sporozoite vaccinees. Selection of CSP-specific mAbs optimal in epitope targeting and affinity will advance preventative and therapeutic antibody development and immunogen design.
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2378-Pos Systematic Biophysical Insights into the Interaction of Anti MERS-CoV Drug Ribavirin with Major Transport Protein in Human Serum:
In-Vitro Studies and Implications in Diabetes and Uremia Fahad Almutairi, Mohammad Rehan Ajmal. Biochemistry, University of Tabuk, Tabuk, Saudi Arabia. The effect of glycosylation in the interaction of antiviral drug ribavirin is studied in detail with major transport protein in blood, human serum albumin (HSA) under in vitro disease mimetic conditions. Ribavirin is an antiviral drug used in treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Tabuk region, kingdom of Saudi Arabia. In present study interaction mechanism for binding of ribavirin with HSA has been elucidated. We explored the binding interaction under physiological environment for alterations in their binding characteristics in co-morbid disease environments namely uremia and diabetes. Binding affinity for drug was found to decrease with glycosylation also there are conformational changes pertaining to binding of drug to target protein. To evaluate the drug binding defects we employed combination of biophysical and bioinformatics techniques. Fluorescence and UV-visible spectroscopy has been used to elucidate the parameters of the drug complexation in presence of urea and glucose. Binding of ribavirin to human serum albumin has been found to decrease both in uremia and diabetic mimetic conditions. Molecular topology of protein has also been studied by dynamic light scattering under different conditions. Ligand binding is an important phenomenon; it essentially controls drug pharmacokinetics. Treatment outcome in MERS-CoV infection have been strongly correlated to diabetes and chronic kidney disease. This study is an attempt to examine binding refashioning under these conditions and will help to understand the changes in drug behavior, this will help in dosage design; appropriate for achieving optimum therapeutic treatment outcome.
2379-Pos
Perturbing Lipopolysaccharide Biosynthesis through Inhibition of Heptosyltransferase I Jozafina Milicaj. Chemistry, Wesleyan University, Middletown, CT, USA. Gram-negative bacteria utilize a variety of extracellular polymeric substances (EPS) as cell wall protectants; a means conserved amongst all gram-negative bacteria. Lipopolysaccharides (LPS) are the EPS in highest abundance on the cell surface with highly hydrophobic o-antigen chains that perturb antimicrobial penetration as well as contributing greatly to species specific virulence. Biosynthesis of the LPS core region begins with a glycosylation reaction catalyzed by Heptosyltransferase I (Hep I). After extensive work to characterize Hep I, inhibitor discovery began with the computational and experimental characterization of a library of compounds from the National Cancer Institute. Numerous compounds were potent in silico binders to Hep I, and these molecules are being evaluated for their ability to inhibit Hep I via kinetic and cell based assays that test for disruption of bacterial growth and LPS biosynthesis. Additionally, compounds identified by our collaborators at the University of Minnesota, have been tested as inhibitors of Hep I using the same approach. It has been demonstrated that many of these tested compounds have bound to Hep I and hindered product formation in ways that require further investigation with methods including but not limited to: isothermal titration calorimetry, circular dichroism, and fluorescence spectroscopy. We are in the process of testing all of these prospective inhibitors via a growth challenge assay where Hep I containing and lacking cell lines will exhibit a different growth pattern in the presence of an inhibitor. Futhermore, total lipid extractions separated through gel electrophoresis show truncation in the LPS of a Hep I containing cell line in the presence of Hep I inhibitors. These cells should then have increased susceptibility to antimicrobials; therefore, as a combined therapy the inhibitor would make traditional antimicrobials effective treatments for resistant bacterial strains.
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